Roles of estrogen receptor α in endometrial carcinoma (Review)

Urick ME and Bell DW: Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 19:510–521. 2019. View Article : Google Scholar : PubMed/NCBI

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Zhou Y, Shen J, Xia L and Wang Y: Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-alpha signaling. Cancer Cell International. 14:5402014. View Article : Google Scholar : PubMed/NCBI

Koskas M, Amant F, Mirza MR and Creutzberg CL: Cancer of the corpus uteri: 2021 update. Int J Gynecol Obstet. 155:45–60. 2021. View Article : Google Scholar

Saito A, Yoshida H, Nishikawa T and Yonemori K: Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. World J Clin Oncol. 12:868–881. 2021. View Article : Google Scholar : PubMed/NCBI

Engelsen IB, Stefansson IM, Akslen LA and Salvesen HB: GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol. 199:543.e1–e7. 2008. View Article : Google Scholar : PubMed/NCBI

Koshiyama M, Konishi I and Fujii S: Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer. Cancer J France. 11:277–283. 1998.

Musicco C, Cormio G, Pesce V, Loizzi V, Cicinelli E, Resta L, Ranieri G and Cormio A: Mitochondrial dysfunctions in type I endometrial carcinoma: Exploring their role in oncogenesis and tumor progression. Int J Mol Sci. 19:20762018. View Article : Google Scholar : PubMed/NCBI

Gullo G, Etrusco A, Cucinella G, Perino A, Chiantera V, Laganà AS, Tomaiuolo R, Vitagliano A, Giampaolino P, Noventa M, et al: Fertility-sparing approach in women affected by stage I and low-grade endometrial carcinoma: An updated overview. Int J Mol Sci. 22:118252021. View Article : Google Scholar : PubMed/NCBI

Tan DSP, Lambros MBK, Marchio C and Reis-Filho JS: ESR1 amplification in endometrial carcinomas: Hope or hyperbole? J Pathol. 216:271–274. 2008. View Article : Google Scholar : PubMed/NCBI

Jongen V, Sluijmer AV and Heineman MJ: The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer. Maturitas. 43:77–85. 2002. View Article : Google Scholar : PubMed/NCBI

AlZaabi A, AlAmri H, ALAjmi G, Allawati M, Muhanna F, Alabri R, AlBusaidi F, AlGhafri S, Al-Mirza AA and Al Baimani K: Endometrial surveillance in tamoxifen and letrozole treated breast cancer patients. Cureus. 13:e200302021.PubMed/NCBI

Travaglino A, Raffone A, Mascolo M, Guida M, Insabato L, Zannoni GF and Zullo F: TCGA molecular subgroups in endometrial undifferentiated/dedifferentiated carcinoma. Pathol Oncol Res. 26:1411–1416. 2020. View Article : Google Scholar : PubMed/NCBI

Barton M, Filardo EJ, Lolait SJ, Thomas P, Maggiolini M and Prossnitz ER: Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol. 176:4–15. 2018. View Article : Google Scholar : PubMed/NCBI

Fuentes N and Silveyra P: Estrogen receptor signaling mechanisms. Donev R: Intracellular Signalling Proteins; pp. pp135–170. 2019

Zhang Z, Qin P, Deng Y, Ma Z, Guo H, Guo H, Hou Y, Wang S, Zou W, Sun Y, et al: The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation. J Neuroinflammation. 15:2062018. View Article : Google Scholar : PubMed/NCBI

Prossnitz ER and Barton M: The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 7:715–726. 2011. View Article : Google Scholar : PubMed/NCBI

Tecalco-Cruz AC, Zepeda-Cervantes J and Ortega-Dominguez B: Estrogenic hormones receptors in Alzheimer's disease. Mol Biol Rep. 48:7517–7526. 2021. View Article : Google Scholar : PubMed/NCBI

Rahman MT, Nakayama K, Rahman M, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Ishikawa N, et al: ESR1 gene amplification in endometrial carcinomas: A clinicopathological analysis. Anticancer Res. 33:3775–3781. 2013.PubMed/NCBI

Lara-Castillo N: Estrogen signaling in bone. Appl Sci Basel. 11:44392021. View Article : Google Scholar

Lebeau A, Grob TJ, Hoist F, Seyedi-Fazlollahi N, Moch H, Terracciano L, Turzynski A, Choschzick M, Sauter G and Simon R: Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J Pathol. 216:151–157. 2008. View Article : Google Scholar : PubMed/NCBI

Guo WY, Zeng SMZ, Deora GS, Li QS and Ruan BF: Estrogen Receptor α (ERα)-targeting compounds and derivatives: Recent advances in structural modification and bioactivity. Curr Top Med Chem. 19:1318–1337. 2019. View Article : Google Scholar : PubMed/NCBI

Krasner C: Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol. 106:76–80. 2007. View Article : Google Scholar : PubMed/NCBI

Rao J, Jiang X, Wang Y and Chen B: Advances in the understanding of the structure and function of ER-alpha 36, a novel variant of human estrogen receptor-alpha. J Steroid Biochem Mol Biol. 127:231–237. 2011. View Article : Google Scholar : PubMed/NCBI

Arao Y and Korach KS: Transactivation Function-1-mediated partial agonist activity of selective estrogen receptor modulator requires homo-dimerization of the estrogen receptor alpha ligand binding domain. Int J Mol Sci. 20:37182019. View Article : Google Scholar : PubMed/NCBI

Jia M, Dahlman-Wright K and Gustafsson J: Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab. 29:557–568. 2015. View Article : Google Scholar : PubMed/NCBI

Bouricha EM, Hakmi M, Akachar J, Zouaidia F and Ibrahimi A: In-silico identification of potential inhibitors targeting the DNA binding domain of estrogen receptor alpha for the treatment of hormone therapy-resistant breast cancer. J Biomol Struct Dyn. 40:5203–5210. 2020. View Article : Google Scholar : PubMed/NCBI

Arao Y and Korach KS: The physiological role of estrogen receptor functional domains. Essays Biochem. 65:867–875. 2021. View Article : Google Scholar : PubMed/NCBI

Tecalco-Cruz AC, Perez-Alvarado IA, Ramirez-Jarquin JO and Rocha-Zavaleta L: Nucleo-cytoplasmic transport of estrogen receptor alpha in breast cancer cells. Cell Signal. 34:121–132. 2017. View Article : Google Scholar : PubMed/NCBI

Skafar DF and Zhao C: The multifunctional estrogen receptor-alpha F domain. Endocrine. 33:1–8. 2008. View Article : Google Scholar : PubMed/NCBI

Zwart W, de Leeuw R, Rondaij M, Neefjes J, Mancini MA and Michalides R: The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci. 123:1253–1261. 2010. View Article : Google Scholar : PubMed/NCBI

Božović A, Mandušić V, Todorović L and Krajnović M: Estrogen receptor Beta: The promising biomarker and potential target in metastases. Int J Mol Sci. 22:16562021. View Article : Google Scholar : PubMed/NCBI

Rocha W, Sanchez R, Deschenes J, Auger A, Hébert E, White JH and Mader S: Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial ishikawa cells. Mol Pharmacol. 68:1852–1862. 2005. View Article : Google Scholar : PubMed/NCBI

Chen X, Yan Q, Li S, Zhou L, Yang H, Yang Y, Liu X and Wan X: Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ER alpha-positive endometrioid adenocarcinoma. Cancer Lett. 314:41–53. 2012. View Article : Google Scholar : PubMed/NCBI

Hermon TL, Moore AB, Yu L, Kissling GE, Castora FJ and Dixon D: Estrogen receptor alpha (ER alpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Archiv. 453:557–569. 2008. View Article : Google Scholar : PubMed/NCBI

Bao W, Zhang Y, Li S, Fan Q, Qiu M, Wang Y, Li Y, Ji X, Yang Y, Sang Z, et al: miR-107-5p promotes tumor proliferation and invasion by targeting estrogen receptor-alpha in endometrial carcinoma. Oncol Rep. 41:1575–1585. 2019.PubMed/NCBI

Wu Y, Zeng K, Wang C, Wang S, Sun H, Liu W, Wang X, Niu J, Cong SY, Zhou X and Zhao Y: Histone acetyltransferase MOF is involved in suppression of endometrial cancer and maintenance of ERα stability. Biochem Biophys Res Commun. 509:541–548. 2019. View Article : Google Scholar : PubMed/NCBI

Kershah SM, Desouki MM, Koterba KL and Rowan BG: Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol Oncol. 92:304–313. 2004. View Article : Google Scholar : PubMed/NCBI

Gao M, Sun PM, Wang JL, Li XP, Zhao C and Wei LH: Different biological effect of estrogen receptor-related receptor alpha in estrogen receptor-positive and -negative endometrial carcinoma. Mol Med Rep. 1:917–924. 2008.PubMed/NCBI

Shiozawa T, Itoh K, Horiuchi A, Konishi I, Fujii S and Nikaido T: Down-regulation of estrogen receptor by the methylation of the estrogen receptor gene in endometrial carcinoma. Anticancer Res. 22:139–143. 2002.PubMed/NCBI

Liu B, Che Q, Qiu H, Bao W, Chen X, Lu W, Li B and Wan X: Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα. PLoS One. 9:e875632014. View Article : Google Scholar : PubMed/NCBI

Song Q, An Q, Niu B, Lu X, Zhang N and Cao X: Role of miR-221/222 in tumor development and the underlying mechanism. J Oncol. 2019:72520132019. View Article : Google Scholar : PubMed/NCBI

Zhang G, Hou X and Gao S: Stimulation of peroxisome proliferator-activated receptor gamma inhibits estrogen receptor alpha transcriptional activity in endometrial carcinoma cells. Oncol Rep. 33:1227–1234. 2015. View Article : Google Scholar : PubMed/NCBI

Uchida S, Saimi M, Li ZL, Miyaso H, Nagahori K, Kawata S, Omotehara T, Ogawa Y and Itoh M: Effects of phosphorylated estrogen receptor alpha on apoptosis in human endometrial epithelial cells. Anat Sci Int. 95:240–250. 2020. View Article : Google Scholar : PubMed/NCBI

Zhang P, Gao K, Jin X, Ma J, Peng J, Wumaier R, Tang Y, Zhang Y, An J, Yan Q, et al: Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover. Cell Death Dis. 6:e16872015. View Article : Google Scholar : PubMed/NCBI

Sentis S, Le Romancer M, Bianchin C, Rostan MC and Corbo L: Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol. 19:2671–2684. 2005. View Article : Google Scholar : PubMed/NCBI

O'Doherty A, Church SW, Russell SEH, Nelson J and Hickey I: Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines. Br J Cancer. 86:282–284. 2002. View Article : Google Scholar : PubMed/NCBI

Li Y, Zhou Y, Mao F, Shen S, Zhao B, Xu Y, Lin Y, Zhang X, Cao X, Xu Y, et al: miR-452 reverses abnormal glycosylation modification of ERα and estrogen resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1. Front Oncol. 10:15092020. View Article : Google Scholar : PubMed/NCBI

Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP and O'Malley BW: The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem. 273:12101–12108. 1998. View Article : Google Scholar : PubMed/NCBI

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al: Activation of the estrogen-receptor through phosphorylation by mitogen-activated protein-kinase. Science. 270:1491–1494. 1995. View Article : Google Scholar : PubMed/NCBI

Vilgelm A, Lian ZL, Wang H, Beauparlant SL, Klein-Szanto A, Ellenson LH and Di Cristofano A: Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten(+/-) mice. Cancer Res. 66:3375–3380. 2006. View Article : Google Scholar : PubMed/NCBI

Kato E, Orisaka M, Kurokawa T, Chino Y, Fujita Y, Shinagawa A and Yoshida Y: Relation between outcomes and expression of estrogen receptor-alpha phosphorylated at Ser(167) in endometrioid endometrial cancer. Cancer Sci. 105:1307–1312. 2014. View Article : Google Scholar : PubMed/NCBI

Lee H and Bai W: Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol. 22:5835–5845. 2002. View Article : Google Scholar : PubMed/NCBI

Ohtake F, Fujii-Kuriyama Y and Kato S: AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem Pharmacol. 77:474–484. 2009. View Article : Google Scholar : PubMed/NCBI

Han SJ, Begum K, Foulds CE, Hamilton RA, Bailey S, Malovannaya A, Chan D, Qin J and O'Malley BW: The dual estrogen receptor α inhibitory effects of the tissue-selective estrogen complex for endometrial and breast safety. Mol Pharmacol. 89:14–26. 2016. View Article : Google Scholar : PubMed/NCBI

Su Y, Zeng K, Liu S, Wu Y, Wang C, Wang S, Lin L, Zou R, Sun G, Luan R, et al: Ubiquitin-specific peptidase 14 maintains estrogen receptor α stability via its deubiquitination activity in endometrial cancer. J Biol Chem. 299:1027342023. View Article : Google Scholar : PubMed/NCBI

Lv Q, Xie L, Cheng Y, Shi Y, Shan W, Ning C, Xie B, Yang B, Luo X, He Q, et al: A20-mediated deubiquitination of ERα in the microenvironment of CD163⁺ macrophages sensitizes endometrial cancer cells to estrogen. Cancer Lett. 442:137–147. 2019. View Article : Google Scholar : PubMed/NCBI

Xu ZX, Liu J, Gu LP, Huang B and Pan XJ: Biological effects of xenoestrogens and the functional mechanisms via genomic and nongenomic pathways. Environmental Rev. 25:306–322. 2017. View Article : Google Scholar

Stefkovich ML, Arao Y, Hamilton KJ and Korach KS: Experimental models models for evaluating non-genomic estrogen signaling. Steroids. 133:34–37. 2018. View Article : Google Scholar : PubMed/NCBI

Wang ZY and Yin L: Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer. Mol Cell Endocrinol. 418:193–206. 2015. View Article : Google Scholar : PubMed/NCBI

Manavathi B, Samanthapudi VSK and Gajulapalli VNR: Estrogen receptor coregulators and pioneer factors: The orchestrators of mammary gland cell fate and development. Front Cell Dev Biol. 2:342014. View Article : Google Scholar : PubMed/NCBI

Che Q, Liu BY, Liao Y, Zhang HJ, Yang TT, He YY, Xia YH, Lu W, He XY, Chen Z, et al: Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17β-estradiol biosynthesis in endometrial carcinoma microenvironment. Int J Cancer. 135:282–294. 2014. View Article : Google Scholar : PubMed/NCBI

Zhang ZP and Teng CT: Estrogen receptor alpha and estrogen receptor-related receptor alpha 1 compete for binding and coactivator. Mol Cell Endocrinol. 172:223–233. 2001. View Article : Google Scholar : PubMed/NCBI

Gao M, Sun PM, Zhao D, Wang JL, Li XP and Wei LH: Regulatory effect of 17beta-estradiol on expression of orphan nuclear receptor ERRalpha in endometrial carcinoma cell lines. Ai Zheng. 25:538–542. 2006.(In Chinese). PubMed/NCBI

Mylonas I, Jeschke U, Shabani N, Kuhn C, Kriegel S, Kupka MS and Friese K: Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res. 25:1679–1686. 2005.PubMed/NCBI

Su T, Qu JJ, Wang K, Li BL, Zhao D, Zhu YP, Ye L, Lu W and Wan XP: Cross-talk between p21-activated kinase 4 and ER alpha signaling triggers endometrial cancer cell proliferation. Oncotarget. 8:68083–68094. 2017. View Article : Google Scholar : PubMed/NCBI

Zhou XH, Xu ST, Song WY and Teng XD: Expression of receptor-binding cancer antigen expressed on SiSo cells in endometrial carcinoma and the correlation thereof with the expression of estrogen receptor subtypes. Zhonghua Yi Xue Za Zhi. 87:1900–1903. 2007.(In Chinese). PubMed/NCBI

Hou X, Zhao M, Wang T and Zhang G: Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. Oncol Rep. 31:1175–1182. 2014. View Article : Google Scholar : PubMed/NCBI

Zhao L, Watanabe M, Yano T, Yanagisawa J, Nakagawa S, Oishi H, Wada-Hiraike O, Oda K, Minaguchi T, Yasugi T, et al: Analysis of the status of the novel estrogen receptor alpha (ERα) coactivator p72 in endometrial cancer and its cross talk with erbB-2 in the transactivation of ERα. Mol Med Rep. 1:387–390. 2008.PubMed/NCBI

Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, Taipaleenmäki H, Ben-Batalla I, Scheller M, Loges S, et al: Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep. 8:460–469. 2014. View Article : Google Scholar : PubMed/NCBI

Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA and Kumar R: Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab. 89:6130–6138. 2004. View Article : Google Scholar : PubMed/NCBI

Thorne AM, Jackson TA, Willis VC and Bradford AP: Protein Kinase C α modulates estrogen-receptor-dependent transcription and proliferation in endometrial cancer cells. Obstet Gynecol Int. 2013:5374792013. View Article : Google Scholar : PubMed/NCBI

Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, et al: p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol. 20:971–983. 2006. View Article : Google Scholar : PubMed/NCBI

Kojima M, Sugimoto K, Kobayashi M, Ichikawa-Tomikawa N, Kashiwagi K, Watanabe T, Soeda S, Fujimori K and Chiba H: Aberrant Claudin-6-adhesion signaling promotes endometrial cancer progression via estrogen receptor α. Mol Cancer Res. 19:1208–1220. 2021. View Article : Google Scholar : PubMed/NCBI

Lee H, Jiang F, Wang Q, Nicosia SV, Yang J, Su B and Bai W: MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol. 14:1882–1896. 2000. View Article : Google Scholar : PubMed/NCBI

Lian Z, De Luca P and Di Cristofano A: Gene expression analysis reveals a signature of estrogen receptor activation upon loss of Pten in a mouse model of endometrial cancer. J Cell Physiol. 208:255–266. 2006. View Article : Google Scholar : PubMed/NCBI

Velarde MC, Zeng Z, McQuown JR, Simmen FA and Simmen RCM: Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells. Mol Endocrinol. 21:2988–3001. 2007. View Article : Google Scholar : PubMed/NCBI

Cheng R, Xue X and Liu X: Expression of IL17A in endometrial carcinoma and effects of IL17A on biological behaviour in Ishikawa cells. J Int Med Res. 48:3000605209505632020. View Article : Google Scholar : PubMed/NCBI

Wang D, Wang M, Hu CE, Shuang T, Zhou Y and Yan X: Expression of the ELAV-like protein HuR in the cytoplasm is associated with endometrial carcinoma progression. Tumor Biol. 35:11939–11947. 2014. View Article : Google Scholar

Gu CJ, Xie F, Zhang B, Yang HL, Cheng J, He YY, Zhu XY, Li DJ and Li MQ: High glucose promotes epithelial-mesenchymal transition of uterus endometrial cancer cells by increasing ER/GLUT4-mediated VEGF secretion. Cell Physiol Biochem. 50:706–720. 2018. View Article : Google Scholar : PubMed/NCBI

Nan F, Wei S, Guan D, Zhang L, Guo Q, Cao S, Liu Y, Liu Y and Sun M: Suppressive efficiency of RASSF1A in endometrial carcinoma via inhabiting estrogen receptor alpha expression and ERK pathway activation. Int J Clin Exp Pathol. 11:577–585. 2018.PubMed/NCBI

Tanwar PS, Zhang L, Roberts DJ and Teixeira JM: Stromal deletion of the APC tumor suppressor in mice triggers development of endometrial cancer. Cancer Res. 71:1584–1596. 2011. View Article : Google Scholar : PubMed/NCBI

Tong H, Ke JQ, Jiang FZ, Wang XJ, Wang FY, Li YR, Lu W and Wan XP: Tumor-associated macrophage-derived CXCL8 could induce ERα suppression via HOXB13 in endometrial cancer. Cancer Lett. 376:127–136. 2016. View Article : Google Scholar : PubMed/NCBI

Zhou XH, Teng XD, Song WY and Wu YJ: Expression of receptor-binding cancer antigen expressed on SiSo cells and estrogen receptor subtypes in the normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer. 18:152–158. 2008. View Article : Google Scholar : PubMed/NCBI

Tian W, Teng F, Gao J, Gao C, Liu G, Zhang Y, Yu S, Zhang W, Wang Y and Xue F: Estrogen and insulin synergistically promote endometrial cancer progression via crosstalk between their receptor signaling pathways. Cancer Biol Med. 16:55–70. 2019. View Article : Google Scholar : PubMed/NCBI

Zhang F, Peng L, Huang Y, Lin X, Zhou L and Chen J: Chronic BDE-47 exposure aggravates malignant phenotypes and chemoresistance by activating ERK through ERα and GPR30 in endometrial carcinoma. Front Oncol. 9:10792019. View Article : Google Scholar : PubMed/NCBI

Saito S, Ito K, Suzuki T, Utsunomiya H, Akahira J, Sugihashi Y, Niikura H, Okamura K, Yaegashi N and Sasano H: Orphan nuclear receptor DAX-1 in human endometrium and its disorders. Cancer Sci. 96:645–652. 2005. View Article : Google Scholar : PubMed/NCBI

Collins F, Itani N, Esnal-Zufiaurre A, Gibson DA, Fitzgerald C and Saunders PTK: The ERβ 5 splice variant increases oestrogen responsiveness of ERαpos Ishikawa cells. Endocr Relat Cancer. 27:55–66. 2020. View Article : Google Scholar : PubMed/NCBI

Bircan S, Ensari A, Ozturk S, Erdogan N, Dundar I and Ortac F: Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol Oncol Res. 11:32–39. 2005. View Article : Google Scholar : PubMed/NCBI

Nakayama H, Sano T, Motegi A, Oyama T and Nakajima T: Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int. 55:707–715. 2005. View Article : Google Scholar : PubMed/NCBI

Wang J, Bao W, Qiu M, Liao Y, Che Q, Yang T, He X, Qiu H and Wan X: Forkhead-box A1 suppresses the progression of endometrial cancer via crosstalk with estrogen receptor α. Oncol Rep. 31:1225–1234. 2014. View Article : Google Scholar : PubMed/NCBI

Chen Z, Yang HJ, Lin Q, Zhu MJ, Yu YY, He XY and Wan XP: Estrogen-ERα signaling and DNA hypomethylation co-regulate expression of stem cell protein PIWIL1 in ER alpha-positive endometrial cancer cells. Cell Commun Signal. 18:842020. View Article : Google Scholar : PubMed/NCBI

Flamini MI, Sanchez AM, Genazzani AR and Simoncini T: Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase. Fertility Sterility. 95:722–726. 2011. View Article : Google Scholar : PubMed/NCBI

Sayeed A, Konduri SD, Liu W, Bansal S, Li F and Das GM: Estrogen receptor alpha inhibits p53-mediated transcriptional repression: Implications for the regulation of apoptosis. Cancer Res. 67:7746–7755. 2007. View Article : Google Scholar : PubMed/NCBI

Zhang R, He Y, Zhang X, Xing B, Sheng Y, Lu H and Wei Z: Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett. 314:155–165. 2012. View Article : Google Scholar : PubMed/NCBI

Chao A, Lin CY, Tsai CL, Hsueh S, Lin YY, Lin CT, Chou HH, Wang TH, Lai CH and Wang HS: Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23). J Mol Med (Berl). 91:249–259. 2013. View Article : Google Scholar : PubMed/NCBI

Hu G, Zhang J, Zhou X, Liu J, Wang Q and Zhang B: Roles of estrogen receptor α and β in the regulation of proliferation in endometrial carcinoma. Pathol Res Pract. 216:1531492020. View Article : Google Scholar : PubMed/NCBI

Saito T, Tanaka R, Wataba K, Kudo R and Yamasaki H: Overexpression of estrogen receptor-α gene suppresses gap junctional intercellular communication in endometrial carcinoma cells. Oncogene. 23:1109–1116. 2004. View Article : Google Scholar : PubMed/NCBI

Zhu Y, Shen J, Gao L and Feng Y: Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncol Rep. 35:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI

Chen R, Zhang M, Liu W, Chen H, Cai T, Xiong H, Sheng X, Liu S, Peng J, Wang F, et al: Estrogen affects the negative feedback loop of PTENP1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma. Cell Death Dis. 10:42018. View Article : Google Scholar : PubMed/NCBI

Scully MM, Palacios-Helgeson LK, Wah LS and Jackson TA: Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells. Horm Cancer. 5:218–231. 2014. View Article : Google Scholar : PubMed/NCBI

Mizumoto H, Saito T, Ashihara K, Nishimura M, Tanaka R and Kudo R: Acceleration of invasive activity via matrix metalloproteinases by transfection of the estrogen receptor-α gene in endometrial carcinoma cells. Int J Cancer. 100:401–406. 2002. View Article : Google Scholar : PubMed/NCBI

Liu Y, Zhao R, Chi S, Zhang W, Xiao C, Zhou X, Zhao Y and Wang H: UBE2C is upregulated by estrogen and promotes epithelial-mesenchymal transition via p53 in endometrial cancer. Mol Cancer Res. 18:204–215. 2020. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang Q, Zhao G, Gu H, Liao H, Zhu Y, et al: Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett. 319:89–97. 2012. View Article : Google Scholar : PubMed/NCBI

Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, et al: Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res. 19:1094–1105. 2013. View Article : Google Scholar : PubMed/NCBI

Yang T, Zhang H, Qiu H, Li B, Wang J, Du G, Ren C and Wan X: EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/β-catenin signaling in endometrial carcinoma. Oncotarget. 7:25712–25725. 2016. View Article : Google Scholar : PubMed/NCBI

Yang T, Ren C, Jiang A, Yu Z, Li G, Wang G and Zhang Q: RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer. Biochem Biophys Res Commun. 489:96–102. 2017. View Article : Google Scholar : PubMed/NCBI

Owens GL, Lawrence KM, Jackson TR, Crosbie EJ, Sayan BS, Kitchener HC and Townsend PA: Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen. Cancer Med. 6:408–415. 2017. View Article : Google Scholar : PubMed/NCBI

Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI

Chuwa AH, Sone K, Oda K, Tanikawa M, Kukita A, Kojima M, Oki S, Fukuda T, Takeuchi M, Miyasaka A, et al: Kaempferol, a natural dietary flavonoid, suppresses 17β-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer. Oncol Lett. 16:6195–6201. 2018.PubMed/NCBI

Abe N, Watanabe J, Tsunoda S, Kuramoto H and Okayasu I: Significance of nuclear p-Akt in endometrial carcinogenesis rapid translocation of p-Akt into the nucleus by estrogen, possibly resulting in inhibition of apoptosis. Int J Gynecological Cancer. 21:194–202. 2011. View Article : Google Scholar : PubMed/NCBI

Wincewicz A, Baltaziak M, Kanczuga-Koda L, Koda M, Sulkowska U, Famulski W and Sulkowski S: STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different estrogen receptor-alpha immunoprofile. Gynecol Endocrinol. 27:536–540. 2011. View Article : Google Scholar : PubMed/NCBI

Sulkowska U, Wincewicz A, Kanczuga-Koda L, Koda M and Sulkowski S: Eventual proapoptotic or anti-apoptotic impact of aberrantly expressed Cx43 and Cx26 can depend on ER-alpha overexpression in human endometrioid adenocarcinoma. Gynecol Endocrinol. 31:604–608. 2015. View Article : Google Scholar : PubMed/NCBI

Abe S, Iwasaki M, Habata S, Mariya T, Tamate M, Matsuura M, Satohisa S and Saito T: ERα increases endometrial cancer cell resistance to cisplatin via upregulation of BAG3. Oncol Lett. 21:202021.PubMed/NCBI

Zhang JW and Peng ZL: Association between the expression of estrogen receptor subunit in endometrial carcinoma and the prognostic factors of endometrial carcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban. 35:843–845. 2004.(In Chinese). PubMed/NCBI

Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, et al: Estrogen receptor alpha wields treatment-specific enhancers between morphologically similar endometrial tumors. Proc Natl Acad Sci USA. 114:E1316–E1325. 2017. View Article : Google Scholar : PubMed/NCBI

Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H and Hayashi S: Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol. 192:93–104. 2002. View Article : Google Scholar : PubMed/NCBI

Shah YM and Rowan BG: The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol. 19:732–748. 2005. View Article : Google Scholar : PubMed/NCBI

Emons G, Mustea A and Tempfer C: Tamoxifen and endometrial cancer: A Janus-Headed Drug. Cancers. 12:25352020. View Article : Google Scholar : PubMed/NCBI

Nikolic I, Andjelkovic M, Zaric M, Zelen I, Canovic P, Milosavljevic Z and Mitrovic M: Induction of mitochondrial apoptotic pathway by raloxifene and estrogen in human endometrial stromal ThESC cell line. Arch Med Sci. 13:293–301. 2017. View Article : Google Scholar : PubMed/NCBI

Wu Y, Niwa K, Onogi K, Tang L, Mori H and Tamaya T: Effects of selective estrogen receptor modulators and genistein on the expression of ER alpha/beta and COX-1/2 in ovarectomized mouse uteri. Eur J Gynaecol Oncol. 28:89–94. 2007.PubMed/NCBI

Boisen MM, Andersen CL, Sreekumar S, Stern AM and Oesterreich S: Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): Promise and challenges. Mol Cell Endocrinol. 418:322–333. 2015. View Article : Google Scholar : PubMed/NCBI

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, et al: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 6:255212016. View Article : Google Scholar : PubMed/NCBI

Amita M, Takahashi T, Igarashi H and Nagase S: Clomiphene citrate down-regulates estrogen receptor-alpha through the ubiquitin-proteasome pathway in a human endometrial cancer cell line. Mol Cell Endocrinol. 428:142–147. 2016. View Article : Google Scholar : PubMed/NCBI

Bae-Jump VL, Zhou C, Boggess JF and Gehrig PA: Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells. Reproductive Sci. 15:1011–1017. 2008. View Article : Google Scholar : PubMed/NCBI

Collins G, Mesiano S and DiFeo A: Effects of metformin on cellular proliferation and steroid hormone receptors in patient-derived, low-grade endometrial cancer cell lines. Reprod Sci. 26:609–618. 2019. View Article : Google Scholar : PubMed/NCBI

Mao X, Dong B, Gao M, Ruan G, Huang M, Braicu EI, Sehouli J and Sun P: Dual targeting of estrogen receptor alpha and estrogen-related receptor alpha: A novel endocrine therapy for endometrial cancer. Onco Targets Ther. 12:6757–6767. 2019. View Article : Google Scholar : PubMed/NCBI

Yamamoto T, Mori T, Sawada M, Kuroboshi H, Tatsumi H, Yoshioka T, Matsushima H, Iwasaku K and Kitawaki J: Estrogen-related receptor-γ regulates estrogen receptor-α responsiveness in uterine endometrial cancer. Int J Gynecol Cancer. 22:1509–1516. 2012.PubMed/NCBI

Watanabe M, Kobayashi Y, Takahashi N, Kiguchi K and Ishizuka B: Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line. J Obstet Gynaecol Res. 34:567–573. 2008. View Article : Google Scholar : PubMed/NCBI

Faigenbaum R, Haklai R, Ben-Baruch G and Kloog Y: Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget. 4:316–328. 2013. View Article : Google Scholar : PubMed/NCBI

Miki Y, Iwabuchi E, Takagi K, Suzuki T, Sasano H, Yaegashi N and Ito K: Co-expression of nuclear heterogeneous nuclear ribonucleic protein K and estrogen receptor α in endometrial cancer. Pathol Res Pract. 231:153795. 2022. View Article : Google Scholar : PubMed/NCBI

Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Øyan AM, Stefansson IM, Kalland KH, et al: Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome. Br J Cancer. 106:1682–1688. 2012. View Article : Google Scholar : PubMed/NCBI

Lin CY, Chao A, Wang TH, Lee LY, Yang LY, Tsai CL, Wang HS and Lai CH: Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells. Oncotarget. 7:60038–60052. 2016. View Article : Google Scholar : PubMed/NCBI

Guo T, Li B and Gu C: Expression of hPEBP4 negatively correlates with estrogen and progesterone receptors in endometrial carcinoma. J Buon. 18:465–470. 2013.PubMed/NCBI

Taylor AH, Al-Azzawi F, Pringle JH and Bell SC: Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides. Anticancer Res. 22:3993–4003. 2002.PubMed/NCBI

Fournier DB, Chisamore M, Lurain JR, Rademaker AW, Jordan VC and Tonetti DA: Protein kinase C α expression is inversely related to ER status in endometrial carcinoma: Possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol Oncol. 81:366–372. 2001. View Article : Google Scholar : PubMed/NCBI

Jongen V, Briet J, de Jong R, Ten Hoor K, Boezen M, van der Zee A, Nijman H and Hollema H: Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 112:537–542. 2009. View Article : Google Scholar : PubMed/NCBI

Ren S, Wu J, Yin W, Liao Q, Gong S, Xuan B and Mu X: Researches on the correlation between estrogen and progesterone receptors expression and disease-free survival of endometrial cancer. Cancer Manag Res. 12:12635–12647. 2020. View Article : Google Scholar : PubMed/NCBI

Mylonas I: Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep. 24:385–393. 2010. View Article : Google Scholar : PubMed/NCBI

Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, et al: Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 43:2434–2444. 2007. View Article : Google Scholar : PubMed/NCBI

Creasman WT: Prognostic significance of hormone receptors in endometrial cancer. Cancer. 71:1467–1470. 1993. View Article : Google Scholar : PubMed/NCBI

Tsujikawa T, Yoshida Y, Kiyono Y, Kurokawa T, Kudo T, Fujibayashi Y, Kotsuji F and Okazawa H: Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET. Eur J Nucl Med Mol Imaging. 38:37–45. 2011. View Article : Google Scholar : PubMed/NCBI

Sho T, Hachisuga T, Nguyen TT, Urabe R, Kurita T, Kagami S, Kawagoe T, Matsuura Y and Shimajiri S: Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma. Int J Gynecol Cancer. 24:102–106. 2014. View Article : Google Scholar : PubMed/NCBI

Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I and Shalev E: Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagnostic Pathology. 9:772014. View Article : Google Scholar : PubMed/NCBI

Pathirage N, Di Nezza LA, Salmonsen LA, Jobling T, Simpson ER and Clyne CD: Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertility Sterility. 86:469–472. 2006. View Article : Google Scholar : PubMed/NCBI

Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, Thomas GD, Mineo C, Yuhanna IS, Kim SH, et al: Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 120:2319–2330. 2010. View Article : Google Scholar : PubMed/NCBI

Duan C, Liu X, Liang S, Yang Z, Xia M, Wang L, Chen S and Yu L: Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma. J Cell Mol Med. 18:863–874. 2014. View Article : Google Scholar : PubMed/NCBI

Ali SH, O'Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S and Dandona P: Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res. 60:7094–7098. 2000.PubMed/NCBI

Ali SH, O'Donnell AL, Mohamed S, Mousa S and Dandona P: Overexpression of estrogen receptor-α in the endometrial carcinoma cell line Ishikawa: Inhibition of growth and angiogenic factors. Gynecol Oncol. 95:637–645. 2004. View Article : Google Scholar : PubMed/NCBI

Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G and Safe S: Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem. 275:22769–22779. 2000. View Article : Google Scholar : PubMed/NCBI

Joshi A, Wang H, Jiang G, Douglas W, Chan JS, Korach KS and Ellenson LH: Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α. Am J Pathol. 180:2536–2547. 2012. View Article : Google Scholar : PubMed/NCBI

Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvänen AC, Kindmark A, Landegren U, Fermér ML, Stiger F, et al: Estrogen receptor alpha gene polymorphism and endometrial cancer risk-a case-control study. BMC Cancer. 8:3222008. View Article : Google Scholar : PubMed/NCBI

Jazaeri O, Shupnik MA, Jazaeri AA and Rice LW: Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol. 74:38–47. 1999. View Article : Google Scholar : PubMed/NCBI

Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY and Qiao J: ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet Gynecol. 205:227.e1–e6. 2011. View Article : Google Scholar : PubMed/NCBI

Bryant W, Snowhite AE, Rice LW and Shupnik MA: The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells. Endocrinology. 146:751–759. 2005. View Article : Google Scholar : PubMed/NCBI

Cancer Genome Atlas Research Network, . Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI

McAlpine J, Leon-Castillo A and Bosse T: The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 244:538–549. 2018. View Article : Google Scholar : PubMed/NCBI

Travaglino A, Raffone A, Gencarelli A, Saracinelli S, Riccardi C, Mollo A, Zullo F and Insabato L: Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 160:579–585. 2021. View Article : Google Scholar : PubMed/NCBI

Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, et al: Improved risk assessment by integrating molecular and clinicopathological factors in Early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 22:4215–4224. 2016. View Article : Google Scholar : PubMed/NCBI

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, et al: Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 28:836–844. 2015. View Article : Google Scholar : PubMed/NCBI

Gao C, Wang Y, Tian W, Zhu Y and Xue F: The therapeutic significance of aromatase inhibitors in endometrial carcinoma. Gynecol Oncol. 134:190–195. 2014. View Article : Google Scholar : PubMed/NCBI

Chen H, Liang M and Min J: Efficacy and safety of Bevacizumab-combined chemotherapy for advanced and recurrent endometrial cancer: A systematic review and Meta-analysis. Balkan Med J. 38:7–12. 2021. View Article : Google Scholar : PubMed/NCBI

Stringer EM and Fleming GF: Hormone therapy plus mTOR inhibitors in the treatment of endometrial carcinoma. Eur Endocrinol. 9:18–21. 2013.PubMed/NCBI

De Jaeghere A, Tuyaerts S, van Nuffel AMT, Lippens L, Hendrix A, Vuylsteke P, Henry S, Trinh XB, Van Dam PA, Aspeslagh S, et al: Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma. Ann Oncol. 32 (Suppl 7):S1449–S1450. 2021. View Article : Google Scholar

Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, et al: Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 135:184–189. 2014. View Article : Google Scholar : PubMed/NCBI

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone Receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol. 30:2718–2724. 2012. View Article : Google Scholar : PubMed/NCBI

Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I and Walsh G; IMPACT Trialists Group, : Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 23:5108–5116. 2005. View Article : Google Scholar : PubMed/NCBI

Roviello G, Francini E, Perrella A, Laera L, Mazzei MA, Guerrini S, Roviello F, Marrelli D and Petrioli R: Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. Cancer Biol Ther. 16:493–497. 2015. View Article : Google Scholar : PubMed/NCBI

Barberio MT, Thomas S, Chien AJ, Rugo HS, Melisko ME, Angelidakis AN, Pawlowska N, Deal T and Munster PN: Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NCT02395627). J Clin Oncol. 34 (Suppl 15):2016.

van Weelden WJ and Massuger LFAG; ENITEC, ; Pijnenborg JMA and Romano A: Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review. Front Oncol. 9:3592019. View Article : Google Scholar : PubMed/NCBI

Hirschfeld M, Ouyang YQ, Jaeger M, Erbes T, Orlowska-Volk M, Zur Hausen A and Stickeler E: HNRNP G and HTRA2-BETA1 regulate estrogen receptor alpha expression with potential impact on endometrial cancer. BMC Cancer. 15:862015. View Article : Google Scholar : PubMed/NCBI

Stanišić V, Malovannaya A, Qin J, Lonard DM and O'Malley BW: OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. J Biol Chem. 284:16135–16145. 2009. View Article : Google Scholar : PubMed/NCBI

Mei S, Ge S, Wang J, Li H, Jing X, Liang K, Zhang X, Xue C, Zhang C and Zhang T: PRMT5 promotes progression of endometrioid adenocarcinoma via ERα and cell cycle signaling pathways. J Pathol Clin Res. 7:154–164. 2021. View Article : Google Scholar : PubMed/NCBI

Tong Z, Liu Y, Yu X, Martinez JD and Xu J: The transcriptional co-activator NCOA6 promotes estrogen-induced GREB1 transcription by recruiting ERα and enhancing enhancer-promoter interactions. J Biol Chem. 294:19667–19682. 2019. View Article : Google Scholar : PubMed/NCBI

Gori I, Pellegrini C, Staedler D, Russell R, Jan C and Canny GO: Tumor necrosis factor-α activates estrogen signaling pathways in endometrial epithelial cells via estrogen receptor α. Mol Cell Endocrinol. 345:27–37. 2011. View Article : Google Scholar : PubMed/NCBI

Hu H, Chen Z, Ji L, Wang Y, Yang M, Lai R, Zhong Y, Zhang X and Wang L: ARID1A-dependent permissive chromatin accessibility licenses estrogen-receptor signaling to regulate circadian rhythms genes in endometrial cancer. Cancer Lett. 492:162–173. 2020. View Article : Google Scholar : PubMed/NCBI

Rodriguez AC, Vahrenkamp JM, Berrett KC, Clark KA, Guillen KP, Scherer SD, Yang CH, Welm BE, Janát-Amsbury MM, Graves BJ and Gertz J: ETV4 is necessary for estrogen signaling and growth in endometrial cancer cells. Cancer Res. 80:1234–1245. 2020. View Article : Google Scholar : PubMed/NCBI

Ring KL, Yates MS, Schmandt R, Onstad M, Zhang Q, Celestino J, Kwan SY and Lu KH: Endometrial cancers with activating KRas mutations have activated estrogen signaling and paradoxical response to MEK inhibition. Int J Gynecol Cancer. 27:854–862. 2017. View Article : Google Scholar : PubMed/NCBI

Fukuda T, Shirane A, Wada-Hiraike O, Oda K, Tanikawa M, Sakuabashi A, Hirano M, Fu H, Morita Y, Miyamoto Y, et al: HAND2-mediated proteolysis negatively regulates the function of estrogen receptor α. Mol Med Rep. 12:5538–5544. 2015. View Article : Google Scholar : PubMed/NCBI

Klinge CM, Jernigan SC and Risinger KE: The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells. Endocrinology. 143:853–867. 2002. View Article : Google Scholar : PubMed/NCBI

Feng Y, Singleton D, Guo C, Gardner A, Pakala S, Kumar R, Jensen E, Zhang J and Khan S: DNA homologous recombination factor SFR1 physically and functionally interacts with estrogen receptor alpha. PLoS One. 8:e680752013. View Article : Google Scholar : PubMed/NCBI

Wu WG, Slomovitz BM, Celestino J, Chung L, Thornton A and Lu KH: Coordinate expression of Cdc25B and ER-α is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res. 63:6195–6199. 2003.PubMed/NCBI

Padmanabhan RA, Nirmala L, Murali M and Laloraya M: CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer. Mol Endocrinol. 25:1499–1512. 2011. View Article : Google Scholar : PubMed/NCBI

Suga S, Kato K, Ohgami T, Yamayoshi A, Adachi S, Asanoma K, Yamaguchi S, Arima T, Kinoshita K and Wake N: An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 105:341–350. 2007. View Article : Google Scholar : PubMed/NCBI

Boggess JF, Zhou C, Bae-Jump VL, Gehrig PA and Whang YE: Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines. Gynecol Oncol. 103:417–424. 2006. View Article : Google Scholar : PubMed/NCBI

Jing X, Peng J, Dou Y, Sun J, Ma C, Wang Q, Zhang L, Luo X, Kong B, Zhang Y, et al: Macrophage ERα promoted invasion of endometrial cancer cell by mTOR/KIF5B-mediated epithelial to mesenchymal transition. Immunol Cell Biol. 97:563–576. 2019. View Article : Google Scholar : PubMed/NCBI

Xu D, Lin TH, Yeh CR, Cheng MA, Chen LM, Chang C and Yeh S: The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth. Biomed Res Int. 2014:7132632014. View Article : Google Scholar : PubMed/NCBI

Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Tremblay A and Tremblay G: EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol. 79:213–225. 2001. View Article : Google Scholar : PubMed/NCBI

Fadiel A, Song J, Tivon D, Hamza A, Cardozo T and Naftolin F: Phenytoin is an estrogen receptor α-selective modulator that interacts with helix 12. Reprod Sci. 22:146–155. 2015. View Article : Google Scholar : PubMed/NCBI

Lian Z, Niwa K, Onogi K, Mori H, Harrigan RC and Tamaya T: Anti-tumor effects of herbal medicines on endometrial carcinomas via estrogen receptor-α-related mechanism. Oncol Rep. 15:1133–1136. 2006.PubMed/NCBI

Zhang W, Chen JH, Aguilera-Barrantes I, Shiau CW, Sheng X, Wang LS, Stoner GD and Huang YW: Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression. Mol Nutr Food Res. 60:2387–2395. 2016. View Article : Google Scholar : PubMed/NCBI

Karaboğa Arslan AK and Yerer MB: α-Chaconine and α-Solanine Inhibit RL95-2 Endometrium Cancer Cell Proliferation by Reducing Expression of Akt (Ser473) and ERα (Ser167). Nutrients. 10:6722018. View Article : Google Scholar : PubMed/NCBI

Leong H, Firestone GL and Bjeldanes LF: Cytostatic effects of 3,3′-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression. Carcinogenesis. 22:1809–1817. 2001. View Article : Google Scholar : PubMed/NCBI

Aoyama H, Couse JF, Hewitt SC, Haseman JK, He H, Zheng X, Majstoravich S, Korach KS and Dixon D: Upregulation of estrogen receptor expression in the uterus of ovariectomized B6C3F1 mice and Ishikawa cells treated with bromoethane. Toxicol Appl Pharmacol. 209:226–235. 2005. View Article : Google Scholar : PubMed/NCBI

Kim HI, Kim T, Kim JE, Lee J, Heo J, Lee NR, Kim NJ and Inn KS: NJK14013, a novel synthetic estrogen receptor-α agonist, exhibits estrogen receptor-independent, tumor cell-specific cytotoxicity. Int J Oncol. 47:280–286. 2015. View Article : Google Scholar : PubMed/NCBI

Karaca B, Bakır E, Yerer MB, Cumaoğlu A, Hamurcu Z and Eken A: Doxazosin and erlotinib have anticancer effects in the endometrial cancer cell and important roles in ERα and Wnt/β-catenin signaling pathways. J Bioch Mol Toxicol. 35:e229052021. View Article : Google Scholar : PubMed/NCBI

Wang J, Liu X, Zhang X, Liu J, Ye S, Xiao S, Chen H and Wang H: Induction of apoptosis by c9, t11-CLA in human endometrial cancer RL 95-2 cells via ERα-mediated pathway. Chem Phys Lipids. 175–176. 27–32. 2013.PubMed/NCBI

Shah YM, Al-Dhaheri M, Dong Y, Ip C, Jones FE and Rowan BG: Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Mol Cancer Ther. 4:1239–1249. 2005. View Article : Google Scholar : PubMed/NCBI